p777 online casino
p777 online casino
A US Justice Department watchdog report has debunked claims by far-right conspiracy theorists who falsely alleged that FBI operatives were secretly involved in the January 6, 2021, attack on the US Capitol by Donald Trump's supporters. or signup to continue reading The report by Justice Department Inspector General Michael Horowitz concluded there was no evidence to suggest that undercover FBI agents participated in the attack on the US Capitol. The report also found the FBI did not authorise any of its informants to enter the building or engage in violence. The FBI has long denied having any involvement by its own staff or its informants in the riots at the Capitol, though conspiracy theories about its role in the attack have persisted. One such false claim pertained to James Ray Epps, an Arizona man who entered the Capitol that day. Epps, who was charged last year with a misdemeanour for entering a restricted building or grounds, was falsely accused by Trump's supporters and by former Fox News host Tucker Carlson of being an undercover government informant. Horowitz's report comes a little more than a month before Trump will be sworn in for his second term as president. He has pledged to grant clemency to many of the people who stormed the Capitol as soon as his first day in office. The report found that the FBI could have done more ahead of the January 6 attack by canvassing its field offices for intelligence from informants to prepare for what was to come. Twenty-six FBI confidential informants were in Washington, D.C., on the day of the attack, the report said. Three of them were tasked with reporting on domestic terrorism case subjects. One of those three entered the Capitol that day, while two others entered a restricted area around the Capitol. The other 23 informants who were in Washington to attend protests did so on their own initiative and were not asked by the bureau to attend the events, the report said. Several of the informants cited in the report on Thursday were tasked with providing the FBI with information related to far-right groups including the Oath Keepers and the Proud Boys. Leaders for both the Oath Keepers and Proud Boys were later prosecuted for their involvement in the Capitol attack, with juries convicting Oath Keepers founder Stewart Rhodes and Proud Boys former chairman Enrique Tarrio of seditious conspiracy and other crimes. In its response to the report, the FBI said it will accept the watchdog's recommendations for how to improve its processes to prepare for future events that could pose domestic security issues. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement AdvertisementMatt Gaetz says he won't return to Congress next year after withdrawing name for attorney general
(The Center Square) – Homeowners in the market for washers and dryers may have better-performing options to choose from in the near future due to a bill limiting the extent of energy efficiency mandates on laundry appliances passing the U.S. House. The Republican-led House Resolution 1612 , or Liberty in Laundry Act, would prohibit the Secretary of Energy from enforcing energy conservation standards for clothes washers or dryers that “are not cost-effective or technologically feasible.” Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Luminar Bolsters Ranks with Tech Industry Leaders
ASX gold shares have been a mixed bag in 2024 despite itself carrying record prices this year. Gold prices have been driven by the combo of increasing demand from investors and central banks buying up the yellow metal by the tonne. But as gold rallied 36% this year to date, the (ASX: XGD), which tracks ASX gold shares, has only climbed 23%. Still an impressive result, but also a wide margin from the underlying spot price's gain. What gives? And what's the outlook for 2025? Let's see what the experts think. What's driving gold's rise? Gold prices have rallied this year due to . Buying from global central banks has been a major driver, with an estimated 900 metric tonnes purchased in 2024. This is well above the decade average of 325 metric tonnes per year. According to Bloomberg, China's central bank has been , picking up its buying pace again in November. China's central bank expanded its gold reserves in November, ending a six-month pause in purchases after prices for the precious metal rose to a record. Bullion held by the People's Bank of China climbed by 160,000 fine troy ounces last month to 72.96 million fine troy ounces, according to official data released on Saturday. The PBOC had added to its stockpiles for 18 consecutive months up until April this year, helping to underpin the strength in bullion prices. Economic uncertainty and geopolitical tensions have also increased demand for gold as a . What's the outlook for gold and ASX gold shares? The future of the gold price, and by extension, ASX gold shares, is up for debate among investor circles. But the view is generally positive. Investment bank UBS reckons gold prices could hit driven by strong demand from central banks and geopolitical instability. Whereas RBC Wealth Management forecasts an , supported by retail investment through . Meanwhile, research firm Natixis expects gold , citing lower interest rates and inflationary pressures as key contributors to its resilience. For reference, Natixis' estimate totals AUD$4,59 per tonne at current exchange rates. So experts reckon gold can trade higher in 2025. But what does this mean for ASX gold shares moving forward? As a reminder, gold miners are price takers, meaning their revenues and cash flows are tied to the price of gold. Under normal circumstances, higher gold prices are good for ASX gold shares. If we look at the current year, ASX gold shares have been clear beneficiaries of the gold rally, somewhat mirroring the rising gold price. Mining giant ( ) has gained 20% year to date, while ( ) is up 26%. Meanwhile, ( ) and ( ) have soared, up 56% and 55% this year, respectively. Consensus estimates have a buy rating on all three of these gold players, except De Grey Mining, which is rated hold. With all this in mind, if the price of gold continues to rise, as experts project it will, this could be positive for ASX gold shares, meaning 2025 could sparkle. Foolish takeaway While no investment is without risk, the outlook for ASX gold shares in 2025 appears promising, according to experts. This is driven by fundamentals of the underlying gold market, of which the outlook is also fairly bullish. Time will tell what happens next.
Phillies signing RHP Jordan RomanoChinese ESG models take the lead in building a sustainable future 12-09-2024 11:56 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Getnews / PR Agency: SHENZHEN HMEDIUM INFORMATION TECHNOLOGY CO.,LTD The second annual ceremony of the environmental, social and governance or ESG models campaign by China Media Group took place in Beijing on December 5th, 2024. Image: https://www.getnews.info/uploads/10101cecf100af20ab6c78509155dad8.jpg At the year-end event of this campaign, eight companies were unveiled as China's ESG models in 2024. They are China Post Group Co., Ltd., China Southern Power Grid Co., Ltd., China Huaneng Group Co., Ltd., HBIS Group Co., LtdKweichow Moutai Group Co., Ltd., LONGi Green Energy Technology Co., Ltd, and Inner Mongolia Yili Industrial Group Co., Ltd. Liu Aili, chairman of China Post Group, Meng Zhenping, chairman of China Southern Power Grid, Wen Shugang, chairman of China Huaneng Group, Yu Yong, chairman of HBIS Group, Zhang Deqin, chairman of Kweichow Moutai Group, Li Zhenguo, founder and CEO of LONGi Green Energy Technology, Lu Weibing, partner and CEO of Xiaomi Group, and Liu Chunxi, executive president of Yili Group, attended the ceremony and interpreted their companies' practices and performances in respect to ESG , showcasing the growing development of Chinese companies in ESG. In recent years, ESG has increasingly become a globally recognized framework for evaluating corporate sustainable development and social responsibility. In order to promote Chinese enterprises to better fulfill their social responsibilities and inject new impetus into global economic growth, CCTV-2 of China Media Group, has co-worked with such authoritative institutions as the State Owned Assets Supervision and Administration Commission of the State Council, the All-China Federation of Industry and Commerce, the State Owned Economic Research Think Tank of the Chinese Academy of Social Sciences, and the China Enterprise Reform and Development Research Society, and held the ESG models campaign ceremony for two consecutive years. The second annual ceremony of ESG models campaign was themed on growth, showcasing how ESG standards are increasingly accepted and followed in the high-quality development of the Chinese economy, as well as the multidimensional changes and progress made by Chinese enterprises in ESG. The outstanding practices of these model companies will further inspire other enterprises in China to move forward in ESG, fulfilling their commitments to the ESG principles on China's path to modernization. Image: https://www.getnews.info/uploads/416d99412109392d6b6b63b636164751.jpg Peng Jianming, a member of China Media Group's editorial board, attended the event and delivered a speech. Emmanuel Faber, chair of the International Sustainability Standards Board, David Atkin, CEO of the Responsible Investment Principles, and Ayla Majid, global president of the Association of Chartered Certified Accountants, all sent video congratulations for the event. The annual ceremony will be aired on CCTV-2 of China Media Group on December 14th, 2024. Image: https://www.getnews.info/uploads/5b54096ba4ab802970f4d57ac32e6083.jpg Media Contact Company Name: Xiamen Zhiding Interactive Media Co., Ltd. Contact Person: Danna Xu Email: Send Email [ http://www.universalpressrelease.com/?pr=chinese-esg-models-take-the-lead-in-building-a-sustainable-future ] Country: China Website: http://www.ideazd.com This release was published on openPR.
REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement Confirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatment Additional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatment Plans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. These results were presented today after market close at an AACR Special Conference in Cancer Research. The company will also hold a webinar on December 10 at 6:30 AM MT / 8:30 AM ET / 1:30 PM GMT to present the preliminary data broadcast from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts with an opportunity to submit questions here . "Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said David Hallett, Ph.D., Chief Scientific Officer of Recursion. "By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level." ELUCIDATE is an ongoing Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of REC-617 in patients with advanced solid tumors. As of the November 15, 2024 data cutoff, preliminary findings include 18 patients with advanced solid tumors who were response evaluable in the monotherapy dose-escalation phase. Doses ranged from 2 mg to 20 mg once daily (QD) and 1 mg twice daily (BID). REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached. While efficacy was not an endpoint in this Phase 1 study, or anticipated in monotherapy, a confirmed durable partial response (PR) by RECIST on REC-617 monotherapy was achieved in a patient with metastatic, platinum-resistant ovarian cancer. The response is on-going after more than 6 months of treatment. This patient had progressed following 4 lines of prior therapy in the advanced setting. In addition, four patients achieved a best response of stable disease (SD) across multiple dose levels for up to 6 months of treatment. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate for ELUCIDATE in H1, 2025. The company expects to present additional ELUCIDATE as well as preclinical REC-617 data at future medical meetings. Summary of Interim REC-617 Monotherapy Dose Escalation Results Study Design & Demographics Phase 1 monotherapy dose escalation in advanced solid tumors Data cutoff as of November 15, 2024 - 19 patients enrolled (18 response evaluable) Heavily pre-treated population (median of 4 prior lines of therapy in the advanced setting) Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea PK/PD Summary REC-617 exceeds CDK7 IC 80 with rapid absorption (Tmax 0.5–2 hours) with a half-life of 5-6 hours Early POLR2A 3-4x modulation suggests ~80–90% target engagement Quick, time-limited target engagement with POLR2A normalization in 24 hours Twice-daily (BID) dosing under investigation Safety Profile/AE Summary Adverse events (AEs) were predominantly low grade, on-target, and reversible upon treatment cessation Early data indicates a favorable safety profile – maximum tolerated dose (MTD) not reached No treatment discontinuations due to AEs 3 treatment related serious adverse events (SAE)s reported in 2/19 patients Events resolved and treatment continued after dose reduction Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea Confirmed Partial Response & Stable Disease Summary One confirmed partial response (PR) by RECIST 1.1 (decrease of more than 30% in the sum of the longest diameters of target lesions + no new lesions + no progression of non target lesions) Partial response (-34%) achieved with reduction of 2 lymph nodes (para-aortic and mesenteric) at Week 16 with normalization of LDH Reduction of tumor marker CA125 from 1249 to 694 kU/L (-44%) Reduction of tumor marker TK1 from 174 to 56 DuA (-68%) Response ongoing after more than 6 months of treatment Patient continues study therapy without need for antiemetics Four additional patients achieved durable (up to 6 months of treatment) response of stable disease (SD) as best response across multiple dose levels All four patients progressed prior to entering the study Three CRC patients (6L-7L) and one NSCLC patient (4L) One patient on 2mg QD and three patients on 10mg QD About REC-617 REC-617 is a potential best-in-class CDK7 inhibitor, precision designed using AI-led approaches, with only 136 novel molecule synthesized from hit to candidate identification in less than 12 months. The molecule is designed to maximize its therapeutic index by enabling the tight control of both the extent and duration of target inhibition. CDK7 inhibition combines many potential benefits such as transcription inhibition, reduction of aberrant kinome activation, cell cycle inhibition, and modulation of estrogen receptor activity. This makes it an attractive target to overcome common resistance pathways associated with CDK4/6 inhibition, which only targets the cell cycle. About ELUCIDATE REC-617 is currently being evaluated as a monotherapy in the ELUCIDATE trial. ELUCIDATE is a multicenter, open-label, two-stage clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of REC-617 in advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer. Both the monotherapy and combination therapy dose escalation portion of the trial will enroll patients across multiple dose levels to determine the optimal biological dose (OBD). The dose expansion phase of the trial will commence upon identification of the OBD. The primary efficacy endpoint of the expansion phase is objective response rate (ORR). About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com , or connect on X (formerly Twitter) and LinkedIn. Media Contact Media@Recursion.com Investor Contact Investor@Recursion.com Forward-Looking Statements This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-617; timing of the Phase 1/2 clinical trial of REC-617; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.'Byju asked business ally to flee to avoid testifying in US court'
